Daily Health Headlines

Diabetes Drug Victoza Might Not Help Advanced Heart Failure Patients

👤by Steven Reinberg 0 comments 🕔Thursday, August 4th, 2016

TUESDAY, Aug. 2, 2016 (HealthDay News) -- The diabetes drug liraglutide (Victoza) doesn't appear to improve heart function in patients with advanced heart failure, a new study finds.

The theory for this trial was that this drug -- from a class of medications called (GLP-1) agonists -- might interact with the heart's GLP-1 receptors on cells and thereby improve heart function.

"We were hoping for a benefit; we didn't see that. It's at best neutral," said lead researcher Dr. Kenneth Margulies. He's a professor of medicine and research director of heart failure and transplantation at the University of Pennsylvania in Philadelphia.

Previous studies found evidence that people with advanced heart failure have insulin resistance of their peripheral muscles and heart muscle, and "this was felt to be a detrimental feature that this type of diabetes medicine might help," he said.

Not only did the drug not help, but it's possible that Victoza might have even been slightly harmful in some patients with advanced heart failure, Margulies said. The study noted that people with type 2 diabetes who were taking Victoza had a slightly higher, though nonsignificant, risk of death and rehospitalization, as well as signs of worsening kidney function.

But, patients using Victoza who develop heart failure shouldn't abruptly stop taking it, he added.

One expert noted that this trial contradicts the findings of another study that found that Victoza lowered the risk of dying from heart disease.

"I suspect that [this] trial is not the final word on the issue," said Dr. John Buse. He's the chief and professor of the division of endocrinology at the University of North Carolina School of Medicine in Chapel Hill.

This new study was small, relatively short in duration and statistically complex, Buse explained. It also involved treating people with diabetes, as well as those without diabetes, he added.

"It does not square with the results of the larger, longer LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results)," Buse said.

The LEADER trial researchers, including Buse, found that over nearly four years, patients with type 2 diabetes and heart disease who were taking Victoza had a lower risk of death from heart disease and stroke, or from any cause, compared with placebo.

"Clearly, the treatment of heart failure in people with diabetes is an area needing more study," Buse said.

In the current study, Margulies and colleagues randomly assigned 300 recently hospitalized advanced heart failure patients to daily injections of Victoza or an inactive placebo.

Over six months, the researchers looked for the number of patients who died, who were readmitted to the hospital for heart failure, or whose disease had stabilized.

Among the 271 patients who completed the study, Victoza had no significant effect on any of the outcomes Margulies' team was looking for.

Among those taking Victoza, 12 percent died. Eleven percent of those receiving placebo died, the study found. Forty-one percent of those taking Victoza were rehospitalized for heart failure, compared with 34 percent of those receiving placebo, the research showed.

In addition, no difference was seen between the groups in measurements of heart function and disease stability, including heart structure and function, six-minute walking distance, and quality of life. And, when the researchers looked at those with and without diabetes, they didn't see any significant differences between the groups.

"In patients who already have severe heart failure, starting this medication to further improve their heart failure does not make sense," Margulies concluded.

But, not everyone necessarily agreed with that conclusion.

"People shouldn't think anything of this study because it didn't show anything," said Dr. Caroline Apovian. She's a professor of medicine and pediatrics at Boston University School of Medicine.

These findings, she said, have to be put in the context of other studies that have shown a benefit in protecting the heart. It's possible that patients in this study were too sick to benefit from Victoza, Apovian said.

"This study took people who were really, really sick and threw a drug at them, and nothing happened," she said. "But these patients may have been too sick to benefit from this drug. If it is started sooner, it may have a real benefit," Apovian said.

Repeated requests for comments from Novo Nordisk, the maker of Victoza, went unanswered.

The report was published Aug. 2 in the Journal of the American Medical Association.

Article Credits / Source

Steven Reinberg / HealthDay

Steven Reinberg wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCES: Kenneth Margulies, M.D., professor, medicine, research director, heart failure/transplantation, University of Pennsylvania, Philadelphia; John Buse, M.D., Ph.D., chief and professor, division of endocrinology, University of North Carolina School of Medicine, Chapel Hill; Caroline Apovian, M.D., professor, medicine and pediatrics, Boston University School of Medicine; Aug. 2, 2016, Journal of the American Medical Association

View More Articles From Steven Reinberg 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Daily Health & Medical News Articles

U.S. Death Toll From Infectious Diseases Unchanged: Study

U.S. Death Toll From Infectious Diseases Unchanged: Study0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- The war against infectious diseases -- medicine versus microbes -- has been holding steady, with the U.S. death rate from these diseases about the same now as it was in 1980, new research says. But ...

2 Doses of HPV Vaccine Effective for Younger Teens

2 Doses of HPV Vaccine Effective for Younger Teens0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- New global research confirms that two doses of the vaccine for HPV, rather than three, can protect younger teens against the sexually transmitted virus. Based on this study and others, U.S. government ...

Tobacco Flavors Draw in Young Folks

Tobacco Flavors Draw in Young Folks0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- Flavored tobacco products attract young people who also consider them less harmful, researchers say. The University of North Carolina team reviewed 40 studies conducted in the United States and other ...

Health Tip: Exercise Can Be a Brain-Booster

Health Tip: Exercise Can Be a Brain-Booster0

(HealthDay News) -- Exercise does more than keep your body healthier. It also affects chemicals in your brain that help you think and focus. The American Council on Exercise says: Exercise improves alertness and focus, and helps you feel ...

New Fetal Views in 3-D

New Fetal Views in 3-D0

MONDAY, Nov. 21, 2016 (HealthDay News) -- Expectant parents may soon be able to view a three-dimensional virtual reality version of the fetus, researchers say. This is possible with new technology that combines MRI and ultrasound data into a ...

View More Daily Health & Medical News Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!